Aurinia Pharmaceuticals (AUPH) Total Current Liabilities (2016 - 2026)

Aurinia Pharmaceuticals has reported Total Current Liabilities for 11 years, with the latest figure at $86.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 26.53% year-over-year to $86.6 million; the trailing twelve-month figure through Mar 2026 stood at $86.6 million (up 26.53% YoY), and the FY2025 full-year result was $93.7 million, down 4.13% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $86.6 million, down from $93.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $97.8 million in Q4 2024, with the low at $33.8 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $67.0 million across 5 years, with a median of $73.9 million in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 78.08% — and 2025, when it dropped 4.13%.
• Aurinia Pharmaceuticals' Total Current Liabilities stood at $46.1 million in 2022, then surged by 67.41% to $77.2 million in 2023, then gained by 26.66% to $97.8 million in 2024, then slipped by 4.13% to $93.7 million in 2025, then retreated by 7.65% to $86.6 million in 2026.
• The last three Total Current Liabilities figures came in at $86.6 million (Q1 2026), $93.7 million (Q4 2025), and $76.2 million (Q3 2025), per Business Quant data.